The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

It's the largest Print with a Purpose collection ever from the Palm Beach brand, to benefit an organization with strong ties ...

A fashion brand founded by a Palm Beacher and a research fundraising organization with strong ties to the island are teaming up to raise awareness for breast cancer research for the sixth year in ...

Eli Lilly & Co. Inc. said Tuesday the Japanese regulator has approved its Kisunla treatment for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment ...

The “Still the One” singer, 59, who served as host for the night, made a statement in a custom Levi’s two-piece denim dress featuring ... “What I wanted to get used to was, ‘What do ...

Eli Lilly’s two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition. These players ...

Indian-origin Pulitzer Prize-winning author Jhumpa Lahiri, has declined the prestigious 2024 Isamu Noguchi Award in protest of the Noguchi Museum’s recently implemented dress code policy. Lahiri’s ...

Donanemab, manufactured by Eli Lilly (LLY), is the latest in a new class of anti-amyloid drugs that deliver antibodies to target beta-amyloid, a protein linked to Alzheimer's disease. Initially ...

The most recent trading session ended with Eli Lilly (LLY) standing at $909.32, reflecting a -1.65% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.4%.

Pulitzer Prize-winning author Jhumpa Lahiri ... an emblem of Palestinian solidarity, following an updated dress code. "Jhumpa Lahiri has chosen to withdraw her acceptance of the 2024 Isamu Noguchi ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...